Last reviewed · How we verify
Pioglitazone and ramipril — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pioglitazone and ramipril (Pioglitazone and ramipril) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pioglitazone and ramipril TARGET | Pioglitazone and ramipril | Takeda | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pioglitazone and ramipril CI watch — RSS
- Pioglitazone and ramipril CI watch — Atom
- Pioglitazone and ramipril CI watch — JSON
- Pioglitazone and ramipril alone — RSS
Cite this brief
Drug Landscape (2026). Pioglitazone and ramipril — Competitive Intelligence Brief. https://druglandscape.com/ci/pioglitazone-and-ramipril. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab